Integra LifeSciences
IART
219 hedge funds and large institutions have $1.62B invested in Integra LifeSciences in 2025 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 74 increasing their positions, 77 reducing their positions, and 30 closing their positions.
611% more call options, than puts
Call options by funds: $512K | Put options by funds: $72K
5.33% more ownership
Funds ownership: 89.87% → 95.2% (+5.3%)
3% more capital invested
Capital invested by funds: $1.57B → $1.62B (+$44.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 77
7% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 30
2% less funds holding
Funds holding: 223 → 219 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$47.6M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$40.6M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$32.1M |
| 4 |
DM
Deerfield Management
New York
|
+$18.7M |
| 5 |
Millennium Management
New York
|
+$9.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$13.5M |
| 2 |
Morgan Stanley
New York
|
-$12M |
| 3 |
D.E. Shaw & Co
New York
|
-$9.22M |
| 4 |
BlackRock
New York
|
-$9.16M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$8.97M |
IART Hedge Fund Activity: Q1 2025 in Review
219 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q1 2025, worth a combined $1.62B — up 2.8% from $1.57B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of IART and 28 opened new positions — a net loss of 2 holders — while 77 trimmed existing stakes and 74 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $47.6M. The largest seller was Capital Research Global Investors, cutting an estimated $13.5M.
- 219 institutional investors held Integra LifeSciences (IART) as of Q1 2025, down from 223 in Q4 2024.
- Funds reported $1.62B of Integra LifeSciences stock for Q1 2025, up 2.8% quarter-over-quarter.
- 28 funds opened new Integra LifeSciences positions in Q1 2025 and 30 closed out, a net change of -2 holders.
- The largest Integra LifeSciences buyer in Q1 2025 was Rubric Capital Management (New York), an estimated $47.6M added.
- The largest Integra LifeSciences seller in Q1 2025 was Capital Research Global Investors, an estimated $13.5M sold.
Based on aggregated 13F filings for Q1 2025.